Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.

[1]  S. Pipe,et al.  1 Bioengineering of Coagulation Factor VIII for Improved Secretion , 2004, Pediatric Research.

[2]  T. Rabbitts,et al.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.

[3]  R. Donahue,et al.  Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  R. Hawley,et al.  Integrative molecular and developmental biology of adult stem cells , 2003, Biology of the cell.

[5]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[6]  A. Ganser,et al.  Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction , 2003, Gene Therapy.

[7]  M. Denaro,et al.  Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Bing Liu,et al.  Isolation of Mouse Marrow Mesenchymal Progenitors by a Novel and Reliable Method , 2003, Stem cells.

[9]  T. Hawley,et al.  Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator , 2003 .

[10]  K. Pasi,et al.  Haemophilias A and B , 2003, The Lancet.

[11]  I. Verma,et al.  Efficient production of human FVIII in hemophilic mice using lentiviral vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  R. Hawley,et al.  Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. , 2003, Current gene therapy.

[13]  F. Luyten,et al.  Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long‐terminal repeats , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  J. Cancelas,et al.  Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene , 2002, Gene Therapy.

[15]  C. Herder,et al.  Generation and characterization of human hematopoietic cell lines expressing factor VIII. , 2002, Journal of hematotherapy & stem cell research.

[16]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[17]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[18]  N. Giri,et al.  In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. , 2001, Human gene therapy.

[19]  R. Hawley.  Progress toward vector design for hematopoietic stem cell gene therapy. , 2001, Current gene therapy.

[20]  K. High.  Gene transfer as an approach to treating hemophilia. , 2001, Circulation research.

[21]  D. Heim,et al.  Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency , 2000, Immunological reviews.

[22]  T. Hawley,et al.  Lentiviral vectors for enhanced gene expression in human hematopoietic cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  J. Tisdale,et al.  Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  I. London,et al.  Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. VandenDriessche,et al.  Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.

[26]  Jiahua Qian,et al.  Prevention and treatment of factor VIII inhibitors in murine hemophilia A. , 2000, Blood.

[27]  P. Watkins,et al.  Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. , 1999, Experimental hematology.

[28]  S. Bidlingmaier,et al.  Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Cheng,et al.  Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. , 1998, Blood.

[30]  R. Morgan,et al.  Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Kaufman,et al.  Mutagenesis of a Potential Immunoglobulin-binding Protein-binding Site Enhances Secretion of Coagulation Factor VIII* , 1997, The Journal of Biological Chemistry.

[32]  R. Mulligan,et al.  Versatile Retrovirus Vector Systems for Regulated Gene Expression In Vitro and In Vivo , 1997, Molecular medicine.

[33]  J. Leonard,et al.  Retroviral Vectors for Production of Interleukin‐12 in the Bone Marrow to Induce a Graft‐Versus‐Leukemia Effect a , 1996, Annals of the New York Academy of Sciences.

[34]  J. Leonard,et al.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Malech,et al.  Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. , 1996, Blood.

[36]  H. Pircher,et al.  Prevention of autoimmune disease by retroviral-mediated gene therapy. , 1995, Journal of immunology.

[37]  R. Morgan,et al.  Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. , 1995, Human gene therapy.

[38]  A. Berns,et al.  Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Hawley,et al.  Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.

[40]  A. Giles,et al.  Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. , 1993, Blood.

[41]  A. van der Eb,et al.  Toward Gene Therapy in Haemophilia A: Retrovirus-Mediated Transfer of a Factor VIII Gene into Murine Haematopoietic Progenitor Cells , 1992, Thrombosis and Haemostasis.

[42]  R. Kaufman,et al.  Retroviral-mediated transfer and amplification of a functional human factor VIII gene. , 1990, Blood.

[43]  T. Hawley,et al.  Comparative analysis of retroviral vector expression in mouse embryonal carcinoma cells. , 1989, Plasmid.

[44]  A. Dorner,et al.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. , 1988, The Journal of biological chemistry.

[45]  H. Karasuyama,et al.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors , 1988, European journal of immunology.

[46]  T. Hawley,et al.  Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Croce,et al.  DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Nakauchi,et al.  Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. , 2001, Human gene therapy.

[49]  J. Dick,et al.  Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. , 2000, Blood.

[50]  R. Mulligan,et al.  Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. , 1996, Gene therapy.

[51]  L. Hoyer.  Medical progress : hemophilia A , 1994 .

[52]  T. Hawley,et al.  Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. , 1992, Journal of immunological methods.

[53]  M. Haine,et al.  Van Damme A. , 1986 .